<DOC>
	<DOCNO>NCT00269152</DOCNO>
	<brief_summary>This study multicenter , open-label , two-arm , randomize , parallel Phase 2 feasibility study pemetrexed combination either cisplatin ( Arm A ) carboplatin ( Arm B ) adjuvant combination-chemotherapy participant completely resect , stage Ib IIa/IIb non-small cell lung cancer ( NSCLC ) . A two-stage design employ independently treatment arm , possibility stop treatment early lack feasibility .</brief_summary>
	<brief_title>Feasibility Study Pemetrexed Combination With Cisplatin Carboplatin Adjuvant Treatment Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically proven nonsmall cell lung cancer stage Ib , IIa IIb Must complete tumor resection pneumonectomy lobectomy Must surgically proven N2 negative Serious concomitant systemic disorder Postoperative complication surgery relate condition A prior malignancy NSCLC unless malignancy diagnose treat least 5 year ago</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>